Table 1.

Clinicopathologic parameters, FOXM1 expression and survival analysis

Variable	No. of patients	Analyzed groups	P-value		FOXM1
			OS	EFS	Positive	Negative	P-value
Sex
Male	44				13	31
Female	62	Male vs. female	0.0028*	0.3047	17	45	0.811
Age
< 20	19				4	15
≥ 20	87	20 < vs. ≥20	0.0189*	0.2499	26	61	0.4279
Chemotherapy
Yes	25				6	19
No	25	Yes vs. No	0.3431	0.8037	4	21	0.4783
N.A.	56
Fusion gene type
SS18-SSX1	30				11	19
SS18-SSX2	14	SSX1 vs. SSX2	0.6271	0.8581	3	11	0.3736
N.A.	62
Depth
Superficial	13				5	8
Deep	91	Deep vs. Superficial	0.4441	0.9057	25	66	0.4243
N.A.	2
Size,cm
< 5	40				8	32
5≥	62	<5 vs. 5≤	0.0012*	0.0335*	22	40	0.0885
N.A.	4
Histological subtype
Mono	69				22	47
Bi	26	Mono vs. bi	0.4225	0.9701	3	23	0.0335*
Poor	3				1	2
Undetermined	8
Necrosis
None	56				13	43
≤ 50 %	26	Necrosis (+) vs. (−)	<0.001*	0.0012*	9	17	0.1526
> 50 %	15				6	9
N.A.	9
Mitotic count
≥ 10/10HPF	70				12	58
< 10/10HPF	31	≥10 vs. <10/10HPF	0.0344*	0.0056*	17	14	0.0002*
N.A.	5
AJCC stage
II	39	II vs. III	0.0304*	0.3734	11	28	0.72
III	44	III vs. IV	<0.001*	-	14	30	0.6579
IV	13				5	8
N.A.	10
FNCLCC
2	69				18	51
3	23	2 vs. 3	<0.001*	<0.001*	10	13	0.123
N.A.	14
FOXM1
Positive	30
Negative	76	Positive vs. negative	0.0128*	0.0043*	-	-	-

AJCC American Joint Committee on Cancer, Bi biphasic synovial sarcoma, EFS event-free survival, FNCLCC French Federation of Cancer Centers, HPF high-power fields, Mono monophasic synovial sarcoma, Poor poorly differentiated synovial sarcoma, NA not available, OS overall survival

*P < 0.05 by log-rank test or chi-square test